medigraphic.com
ISSN 2007-6800 (Print)

2020, Number S1

<< Back Next >>

Rev Mex Traspl 2020; 9 (S1)

ABO-incompatible kidney transplantation

Parra-Ávila I

Language: Spanish
References: 17
Page: 120-124
PDF size: 180.99 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Takahashi K. A new concept of accommodation in ABO incompatible kidney transplantation. Clin Transplant. 2005; 19: 76-85.

  2. Landsteiner K. Über Agglutinationserscheinungen normalen menschlichen Blutes [German]. Wien Klin Wochenschr. 1901; 14: 1132-1134.

  3. Oriol R. ABH and related tissue antigens. Biochem Soc Trans. 1987; 15: 596-599.

  4. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990; 345: 229-233.

  5. Rieben R, Bbuchs JP, Flückiger E, Nydegger UE. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories. Transfusion. 1991; 31: 607-615.

  6. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest. 1955; 34: 327-382.

  7. Alexandre GP, Squifflet JP, De Bruyčre M et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987; 19: 4538-4542.

  8. Ishida H, Tanabe K, Toma H, Akiba T. Therapeutic apheresis therapy for ABO-incompatible renal transplantations. Ther Apher Dial. 2003; 7 (6): 520-528.

  9. Thielke J, Kaplan B, Benedetti E. The role of ABO-incompatible living donors in kidney transplantation: state of the art. Semin Nephrol. 2007; 27 (4): 408-413.

  10. Toki D, Ishida H, Horita S et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int. 2009; 22 (4): 447-454.

  11. Marino R, Martínez-Juárez I, Marino-Vázquez L et al. Comportamiento de células CD19+ durante 12 meses postaplicación de dosis única de rituximab en pacientes con rechazo humoral: resultados clínicos e histológicos. Rev Mex Traspl 2018; 7 (S1): S7-S8.

  12. Breimer ME, Jovall PA. Structural characterization of a blood group A heptaglycosylceramide with globo-series structure. The major glycolipid based blood group A antigen of human kidney. FEBS Lett. 1985; 179: 165-172.

  13. Breimer ME, Molne J, Norden G, Rydberg L, Thiel G, Svalander CT. Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and secretor status. Transplantation. 2006; 82 (4): 479-485.

  14. Zschiedrich S, Kramer-Zucker A, Janigen B et al. An update on ABO incompatible kidney transplantation. Transpl Int. 2015; 28: 387-397.

  15. Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation. 2003; 75 (7): 971-977.

  16. Locke JE, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant. 2007; 7 (4): 842-846.

  17. de Weerd AE, Betjes MGH. ABO-incompatible kidney transplant outcomes: a meta-analysis. Clin J Am Soc Nephrol. 2018; 13 (8): 1234-1243.




2020     |     www.medigraphic.com